TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Phase III Controlled Clinical Study of NPO-11 in Patients Undergoing Gastric Endoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Inpatients or outpatients of either sex who visit medical institutions for treatment or follow-up of confirmed or suspected upper gastrointestinal disease (symptoms) and meet the criteria (1) and (2) below will be enrolled in the study. Patients have to provide written informed consent for voluntary participation in the study.~1. Patients who need gastric endoscopy (except for endoscopy with a scope of \<9 mm in diameter, emergency endoscopy and endoscopy for comprehensive medical examination)~2. Patients who are older than 20 years at the time of consent~Exclusion Criteria:~Patients who meet any of the following criteria will be excluded from the study. The criteria (2) to (5) will be confirmed during endoscopy. Patients who meet any of these criteria will be withdrawn from the study at the time of confirmation.~1. Patients with a history of surgery to the upper gastrointestinal tract~2. Patients with severe gastric stenosis or deformation which makes observation of gastric peristalsis difficult~3. Patients with upper gastrointestinal bleeding which requires hemostasis~4. Patients with reflux esophagitis (Los Angeles classification: B, C or D)~5. Patients with gastric or duodenal ulcers in active stage~6. Patients on cancer treatment (chemotherapy or radiotherapy)~7. Patients with impaired cardiac function (NYHA functional classification: III or IV)~8. Patients with a history of shock or hypersensitivity to l-menthol or peppermint oil (mint oil)~9. Patients with a history of shock or hypersensitivity to lidocaine hydrochloride~10. Pregnant or lactating women, women of childbearing potential, or women who plan to become pregnant during the study~11. Patients who have been exposed to NPO-11~12. Patients who have received other investigational drugs within four months before consent or who are participating in other clinical studies~13. Patients otherwise ineligible for participation in the study in the investigator's or subinvestigator's opinion

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- N (Type: ACTIVE_COMPARATOR): None
- P (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Terlipressin Versus Placebo to Treat Hepatorenal Syndrome Type 1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic, or acute liver disease~* Rapidly progressive reduction in renal function, e.g. doubling of serum creatinine to \>2.5 mg/dL in less than two weeks.~* No sustained improvement in renal function after diuretic withdrawal and plasma volume expansion~* Proteinuria \<500 mg per day~* No evidence of granular casts in urinalysis or ultrasonographic evidence of obstructive uropathy or parenchymal renal disease~Exclusion Criteria:~* Ongoing shock~* Uncontrolled bacterial infection~* Current significant fluid losses~* Current or recent treatment with nephrotoxic drugs (e.g. NSAIDs or aminoglycosides within 4 weeks)~* Acute liver disease due to factors known to be also directly nephrotoxic (e.g. acetaminophen overdose)~* Confirmed pregnancy~* Severe cardiovascular disease~* Evidence of intrinsic or parenchymal renal disease (e.g. acute tubular necrosis)~* Participation in other clinical studies within 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Terlipressin (Type: EXPERIMENTAL): Terlipressin
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized, Controlled Study of Two At-Home Self-Guided Virtual Reality Interventions for Adults With Social Anxiety Disorder.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is male or female, aged 18 or above.~* Subject has English fluency and literacy.~* Subject meets the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, (DSM-5) criteria for Social Anxiety Disorder~* Subject has a total Liebowitz Social Anxiety Scale (LSAS) score at Screening of ≥ 70.~Exclusion Criteria:~* Subject has significant visual, auditory or balance impairment~* Subject has history of photosensitive epilepsy or seizure disorder~* Subject has history of motion sickness or medical condition predisposing to nausea or dizziness.~* Subject has injuries, inflammation or infection affecting the eyes, ears or face that would make the use of the hardware uncomfortable.~* Subject has, current or lifetime history of meeting DSM-5 criteria for schizophrenia spectrum or other psychotic disorder, bipolar or related disorder, major neurocognitive disorder, neurodevelopmental disorder of greater than mild severity or of a severity that impacts the subject's ability to consent, follow study directions, or otherwise safely participate in the study; posttraumatic stress disorder, major depressive disorder (MDD) with psychotic features, borderline or antisocial personality disorder~* Subject has met DSM-5-based criteria for Alcohol or Substance Use Disorder (other than nicotine or caffeine) within one (1) year prior to Screening.~* Subject has received ketamine, esketamine, arketamine, or psychedelic therapies (eg, psilocybin, methylenedioxymethamphetamine \[MDMA\]) for MDD or any psychiatric condition within one (1) year prior to Screening.~* In the opinion of the Investigator: (a) study participation may pose a significant or undue risk to the subject; (b) the subject is unlikely to successfully complete all of the requirements of the study per protocol; or (c) study participation may adversely impact the integrity of the data or the validity of the study results.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- BVR-100 (Type: EXPERIMENTAL): Experimental at-home VR intervention for the treatment of SAD
- BES-100 (Type: ACTIVE_COMPARATOR): Active at-home VR intervention comparator

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Surgicel Reduces Ovarian Endometriomas Recurrence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Endometriosis-related clinical manifestations (infertility, pelvic pain or pelvic mass)~* Unilateral \& unilocular endometrioma (≥5 cm),~* Rapidly growing endometrioma~* Good ovarian reserve (antimullerian hormone {AMH} \> 1 ng/ml \& antral follicular count {AFC} \> 4).~Exclusion Criteria:~* Recurrent \& bilateral cases~* Patients who were unfit for surgery, suffered chronic diseases (e.g. cardiac disease or diabetes)~* PATIENTS had any contraindication for laparoscopic surgery (excessive anterior abdominal wall scarring) .

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- drainage only (Type: NO_INTERVENTION): 50 patients underwent laparoscopic fenestration and electrocautery of the endometrioma cyst wall
- cystectomy only (Type: NO_INTERVENTION): 50 patients underwent laparoscopic excision of the endometrioma cyst wall
- drainage & Surgicel (Type: ACTIVE_COMPARATOR): 50 patients underwent laparoscopic fenestration of the endometrioma cyst wall. Insertion of 4 pieces of SURGICEL® inside the cyst cavity
- cystectomy & Surgicel (Type: ACTIVE_COMPARATOR): 50 patients underwent laparoscopic excision of the endometrioma cyst wall. Insertion of 4 pieces of SURGICEL® inside the remaining ovarian tissues.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial Comparing Tiotropium Inhalation Capsules vs Placebo in Chronic Obstructive Pulmonary Disease (COPD).

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~All subjects must have a diagnosis of Chronic Obstructive Pulmonary Disease (COPD) according to Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) guideline criteria:~post-bronchodilator Forced Expiratory Volume in one Second/Forced Vital Capacity (FEV1/FVC) ratio \< 70% (visit 1).~Subjects must be GOLD Stage II and have a post-bronchodilator FEV1 \>50% and \< 80% of predicted normal (visit 1). Subjects must be current or ex-smokers with a smoking history of \>=10 pack years.~Subjects must have a Medical Research Council (MRC) dyspnea score \>= 2.~Exclusion criteria:~Subjects who have been treated with maintenance medications for chronic respiratory disease within six months prior to screening.~Subjects with significant diseases other than COPD. Subjects on chronic systemic corticosteroids.~Subjects with any upper and/or lower respiratory tract infection or COPD exacerbation in the 6 weeks prior to the initial visit 1 or during the screening period prior to visit 3 Subjects with a recent (past 6 months) myocardial infarction, any unstable or life threatening cardiac arrhythmia requiring intervention or change in drug therapy during the last year; or who have been hospitalized for cardiac failure during the past year.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): Oral inhalation once daily of placebo matching tiotropium via handihaler
- tiotropium (Type: EXPERIMENTAL): Oral inhalation once daily of 18mcg tiotropium via handihaler

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Specified Drug-Use Survey on Vedolizumab for IV Infusion 300 mg [Ulcerative Colitis]

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Have moderate or severe active UC~2. Have inadequate response to existing therapies~Exclusion Criteria:~Patients with any contraindication for vedolizumab

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vedolizumab 300 mg (Type: None): Vedolizumab IV infusion 300 mg, at Weeks 0, 2 and 6, and every 8 weeks thereafter, for up to 54 weeks. Participants will receive IV infusion as part of routine medical care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of High Dose Parenteral Ascorbic Acid On Microcirculation In Sepsis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with sepsis or septic shock within the first 24 hours after ICU admission.~Exclusion Criteria:~* Age \< 18 years,~* Pregnancy,~* Advanced malignancy,~* History of kidney stone, glucose-6-phosphate deficiency, hemochromatosis, or solid organ transplantation,~* Oral mucosal inflammation or injury or technical difficulties in obtaining sublingual images.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ascorbic acid (Type: EXPERIMENTAL): Patients received a high dose of intravenous ascorbic acid in four equal parts daily for 96 hours.~Images of sublingual microcirculation were obtained at a baseline, after 0.5, 6, 12, 24, 48, 72, and 96 hours.
- Placebo (Type: PLACEBO_COMPARATOR): Patients received placebo solution matching ascorbic acid solution as four equal parts daily for 96 hours. Images of sublingual microcirculation were obtained at a baseline, after 0.5, 6, 12, 24, 48, 72, and 96 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Placebo-controlled Study of Levetiracetam In Children (1mo to 4yrs of Age) With Partial Onset Seizures.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pediatric patients from 1 month to less than 4 years of age~* Pediatric patients diagnosed with refractory partial onset seizures, on a stable regimen of one to two other anti-epileptic drugs and at least 2 partial onset seizures per week in the two weeks prior to screening~* Patients must have two partial onset seizures (with corresponding clinical event) during the 48-hour video EEG at screening~Exclusion Criteria:~* A ketogenic diet~* Previous exposure to levetiracetam~* Seizures too close together to count accurately~* Treatable seizure etiology~* Current diagnosis of Lennox-Gastaut Syndrome or epilepsy secondary to a progressing cerebral disease~* Diagnosis of a terminal illness

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 4 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Matching oral solution to Levetiracetam b.i.d. (twice a day) for a maximum treatment duration of 20 days.
- Levetiractem (Type: EXPERIMENTAL): 10 % oral solution Levetiracetam b.i.d. (twice a day) for a maximum treatment duration of 20 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Vitamin D Repletion in Hemodialysis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \> 18 years~2. Chronic hemodialysis treatments for at least 2 consecutive months~3. 25OH-Vitamin D level \< 25 ng/mL (inclusion criteria for randomization)~Exclusion Criteria:~1. History of acute renal failure requiring dialysis with potential for renal recovery~2. History of HIV/AIDS~3. Inability to provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- No treatment (standard of care) (Type: NO_INTERVENTION): Patients will be randomized in a 3:2 ratio to oral Vitamin D treatment, or standard of care (no repletion).
- Vitamin D repletion (Type: EXPERIMENTAL): Patients will be randomized in a 3:2 ratio to oral Vitamin D treatment, or standard of care (no repletion).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Multicenter Hologic Tomosynthesis Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female~* Any ethnic origin~* No contraindication of routine bilateral mammography~Exclusion Criteria:~* Any contraindications to mammographic screening, including but not limited to:~* Significant existing breast trauma~* Pregnancy~* Lactating~* Previous surgical biopsy~* Previous breast cancer~* Placement of an internal breast marker~* Breast implants~* Unable to understand and execute written informed consent~* Breasts are too large to be imaged on the 24 cm by 29 cm detector with a single exposure

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Biopsy (Type: OTHER): subjects presenting for a breast biopsy procedure, subject will be imaged before her biopsy procedure with the investigational 2D plus 3D mammography system
- screening (Type: OTHER): subjects presenting for routine asymptomatic mammograms and will then have an investigational 2D plus 3D mammogram

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Colesevelam HCl, Rosiglitazone, Sitagliptin on Control of Blood Glucose and Lipids in Type 2 Diabetes Patients Whose Blood Glucose Isn't Completely Controlled With Metformin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* HbA1C 7.0 % to 10.0% on metformin monotherapy; may be withdrawn from other (non-metformin) drugs if HbA1C is 6.5% to 9.5 % at screening.~Exclusion Criteria:~* Subjects currently treated with a thiazolidinedione are excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- colesevelam (Type: EXPERIMENTAL): colesevelam tablets 625 mg
- rosiglitazone (Type: ACTIVE_COMPARATOR): rosiglitazone maleate 4mg
- sitagliptin (Type: ACTIVE_COMPARATOR): sitagliptin phosphate tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed pathologic diagnosis of a solid tumor that is not curable with available therapies for which HKI-272 plus vinorelbine is a reasonable treatment option (part 1 only) or Confirmed pathologic diagnosis of ErbB-2-positive breast cancer (current stage IV) in female subjects for which vinorelbine plus HKI-272 is a reasonable treatment option (part 2 only).~* At least 1 prior antineoplastic chemotherapy treatment regimen for metastatic disease and at least 1 prior treatment with a trastuzumab-containing regimen for at least 6 weeks, for metastatic disease or subject relapsing under adjuvant treatment (part 2 only).~* At least 1 measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST).~Exclusion Criteria:~* More than 2 prior antineoplastic treatment regimens (excluding hormonotherapy) for metastatic disease. Subjects who relapsed under adjuvant treatment shouldn't have received more than one line of chemotherapy for metastatic disease (part 2 only).~* Prior treatment with vinorelbine for metastatic setting, or prior treatment with any ErbB-2 targeted agents except trastuzumab (part 2 only). Up to 20 subjects with ErbB-2-overexpressing metastatic breast cancer who have been previously exposed to lapatinib but are not refractory to lapatinib may be enrolled in part 2.~* Prior treatment with anthracyclines with a cumulative dose of doxorubicin of greater than 400 mg/m2, or of epirubicin dose of greater than 800 mg/m2, or the equivalent dose for other anthracyclines or derivatives (part 2 only).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- neratinib 160 mg + vinorelbine (Type: EXPERIMENTAL): neratinib 160 mg tablets administered daily by mouth, vinorelbine 25 mg/m\^2 administered IV on day 1 and day 8 of 21 day cycle
- neratinib 240 mg + vinorelbine (Type: EXPERIMENTAL): neratinib 240 mg tablets administered daily by mouth, vinorelbine 25 mg/m\^2 administered IV on day 1 and day 8 of 21 day cycle
- neratinib 240 mg + vinorelbine, No Prior Lapatinib (Type: EXPERIMENTAL): neratinib 240 mg tablets administered daily by mouth, vinorelbine 25 mg/m\^2 administered IV on day 1 and day 8 of 21 day cycle
- neratinib 240 mg + vinorelbine, Prior Lapatinib (Type: EXPERIMENTAL): neratinib 240 mg tablets administered daily by mouth, vinorelbine 25 mg/m\^2 administered IV on day 1 and day 8 of 21 day cycle

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete